| MX2009002046A              (en) | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders. | 
| BRPI0814503A2              (en)* | 2007-07-09 | 2017-05-16 | Astrazeneca Ab | compound, use of a compound, methods for producing an antiproliferative effect in a warm-blooded animal, and for treating a disease, and, pharmaceutical composition | 
| KR20100042280A              (en)* | 2007-07-09 | 2010-04-23 | 아스트라제네카 아베 | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k | 
| US20100311776A1              (en)* | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and their Use | 
| EP2240021A4              (en)* | 2008-01-30 | 2011-08-17 | Glaxosmithkline Llc | Novel seh inhibitors and their use | 
| EP2240025A4              (en)* | 2008-01-30 | 2012-03-28 | Glaxosmithkline Llc | NOVEL sEH INHIBITORS AND THEIR USE | 
| TW200948362A              (en)* | 2008-04-09 | 2009-12-01 | Mitsubishi Tanabe Pharma Corp | New compounds and their uses | 
| GB0818241D0              (en)* | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use | 
| CA2755554C              (en)* | 2009-04-17 | 2013-09-24 | Wyeth Llc | Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses | 
| UA110697C2              (en) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | USE OF TOR KINASE INHIBITORS FOR TREATMENT OF TUMOR DISEASES IN A PATIENT WITH A REDUCED PAMPK PROTEIN AND / OR AMPK ACTIVITY | 
| SA111320519B1              (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl compounds for use as ATR inhibitors | 
| MX2014001246A              (en) | 2011-08-03 | 2014-06-11 | Signal Pharm Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status. | 
| WO2013041457A1              (en)* | 2011-09-22 | 2013-03-28 | Msd Oss B.V. | N-piperidin-4-yl derivatives | 
| AU2013203714B2              (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity | 
| KR102242505B1              (en) | 2013-04-17 | 2021-04-20 | 시그날 파마소티칼 엘엘씨 | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | 
| BR112015026238A8              (en) | 2013-04-17 | 2019-12-24 | Signal Pharm Llc | dihydropyrazino-pyrazine compound, pharmaceutical composition comprising it, use of the compound, methods to inhibit or measure phosphorylation and to inhibit protein kinase activity, as well as a kit | 
| UA115805C2              (en) | 2013-04-17 | 2017-12-26 | Сігнал Фармасьютікалз, Елелсі | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | 
| KR20160004273A              (en) | 2013-04-17 | 2016-01-12 | 시그날 파마소티칼 엘엘씨 | PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE | 
| KR102240356B1              (en) | 2013-04-17 | 2021-04-14 | 시그날 파마소티칼 엘엘씨 | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | 
| WO2014172426A1              (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines | 
| KR20160002792A              (en) | 2013-04-17 | 2016-01-08 | 시그날 파마소티칼 엘엘씨 | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethyoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer | 
| CN109503591B              (en) | 2013-05-29 | 2022-03-01 | 西格诺药品有限公司 | Pharmaceutical compositions of dihydropyrazinopyrazine compounds, solid forms thereof and their use | 
| WO2015160880A1              (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF | 
| NZ714742A              (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use | 
| KR102496364B1              (en)* | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Smyd inhibitors | 
| CN110996955A              (en) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |